ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: FR-PO275

Effect of Enalapril in a Novel Human Orthologous Rat Model of Autosomal Recessive Polycystic Kidney Disease With Salt-Sensitive Hypertension

Session Information

Category: Genetic Diseases of the Kidneys

  • 1101 Genetic Diseases of the Kidneys: Cystic

Authors

  • Yoshimura, Aya, Fujita Health University, Toyoake, Aichi, Japan
  • Matsuyama, Eriko, Fujita Health University, Toyoake, Aichi, Japan
  • Watanabe, Takashi, Fujita Health University, Toyoake, Aichi, Japan
  • Sakata, Miwa, Fujita Health University, Toyoake, Aichi, Japan
  • Shirozu, Takahiro, Fujita Health University, Toyoake, Aichi, Japan
  • Kugita, Masanori, Fujita Health University, Toyoake, Aichi, Japan
  • Kumamoto, Kanako, Fujita Health University, Toyoake, Aichi, Japan
  • Takizawa, Akiko, Medical College of Wisconsin, Milwaukee, Wisconsin, United States
  • Dwinell, Melinda R., Medical College of Wisconsin, Milwaukee, Wisconsin, United States
  • Hirabayashi, Masumi, National Institute for Physiological Sciences, Okazaki, Aichi, Japan
  • Yamaguchi, Tamio, Suzuka University of Medical Science, Suzuka, Mie, Japan
  • Takahashi, Kazuo, Fujita Health University, Toyoake, Aichi, Japan
  • Nagao, Shizuko, Fujita Health University, Toyoake, Aichi, Japan
Background

One of the causes of hypertension in autosomal recessive polycystic kidney disease (ARPKD) is enhanced salt reabsorption in the collecting duct with increased expression of ENaC (Kaimori et al. 2017), which is targeted by the renin receptor in angiotensin II-induced hypertension (Peng et al. 2017). Recently, the SS-PCK novel rat model of ARPKD with salt-sensitive hypertension was established by introducing the pkhd1 gene from the PCK rat onto the Dahl salt-sensitive (SS) background. In the current study, we investigated pathophysiological characteristics of SS-PCK rats, and the effect of ACEI treatment on hypertension and renal disease progression.

Methods

PCK and Sprague Dawley (SD) rats were obtained from Charles River, and SS and SS-PCK rats were from Medical College of Wisconsin. Males were given standard chow with normal salt level. Furthermore, Enalapril was administrated in SS-PCK rats from 5 to 16 weeks of age. Blood pressure, serum urea nitrogen (SUN) and creatinine (Cre) were measured and kidneys were provided for histology (H&E, PAS and sirius red stains), immunohistochemistry (Ki67 and TGF-β) and immunoblotting (α-, β-, γ-ENaC subunits) analyses.

Results

At 18 weeks of age, blood pressure level was higher in SS-PCK rats compared to either PCK, SS or SD rats. Renal expression of ENaC subunits in SS-PCK was higher than in PCK, SS or SD rats. In SS-PCK compared with PCK, Ki67 expression, kidney weight/body weight and cyst area/section were lower, whereas severe glomerular sclerotic area was higher. Enalapril treatment in SS-PCK ameliorated hypertension, renal cyst formation and glomerulosclerosis, with reduction of Cre, SUN, fibrotic area, and expression level of renal ENaC subunits, Ki67 and TGF-β.

Conclusion

Current findings suggest that the novel rat model of ARPKD with salt-sensitive hypertension could be useful to determine the mechanism of disease progression. By using this strain, it is speculated that ACEI may have a therapeutic potential in ARPKD with salt-sensitive hypertension by reducing ENaC expression.

Funding

  • Government Support – Non-U.S.